← All organizations
Highest phase reached
Phase 3
First clinical trial
Dec 1, 2014First marketed drug
Jun 26, 2024First NDA
Jun 26, 2024Last known activity
Oct 6, 2025
Acquired by Merck on Jul 9, 2025
Timeline
2000s
- Jun 1, 2005
Verona Pharma plc— Founded
2020s
- Jun 26, 2024
ensifentrine— NDA Organization
- Jul 9, 2025
Merck— Acquired By
Drugs by trial phase (8 distinct, 19 trials)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (6 own, 0 via acquisition)
Indications
Marketed drugs (1)
Recent trials (19)
- NCT07132983Lead sponsorPhase 2Oct 6, 2025
- NCT07016412Lead sponsorPhase 2Jul 31, 2025
- NCT06559150Lead sponsorPhase 2Sep 11, 2024
- NCT06545500Lead sponsorPhase 2Aug 16, 2024
- NCT06460493Lead sponsorPhase 3Jun 11, 2024
- NCT05270525Lead sponsorPhase 2May 27, 2022
- NCT04535986Lead sponsorPhase 3Sep 29, 2020
- NCT04542057Lead sponsorPhase 3Sep 22, 2020
- NCT04527471Lead sponsorPhase 2Sep 4, 2020
- NCT03937479Lead sponsorPhase 2May 1, 2019
- NCT04091360Lead sponsorPhase 2Apr 29, 2019
- NCT04027439Lead sponsorPhase 2Dec 10, 2018
- NCT03673670Lead sponsorPhase 2Jul 16, 2018
- NCT03443414Lead sponsorPhase 2Jun 1, 2017
- NCT02919995Lead sponsorPhase 2Feb 1, 2017
Details
- Founded
- London, GB Jun 1, 2005
- First NDA
- Jun 26, 2024
- Last known activity
- Oct 6, 2025